Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial (Q36801223)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 January 2016

Language	Label	Description	Also known as
English	Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial	scientific article published on 21 January 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ming Lu

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Xicheng Wang

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Lin Shen

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jun Jia

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jifang Gong

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jie Li

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jian Li

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Yan Li

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Xiaotian Zhang

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Zhihao Lu

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jun Zhou

11

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Xiaodong Zhang

12

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

publication date

21 January 2016

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

107

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

486-490

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

29 September 2017

A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

29 September 2017

Cancer trends in China

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

29 September 2017

A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

29 September 2017

Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

29 September 2017

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

29 September 2017

Oesophageal cancer: new developments in systemic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

29 September 2017

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

29 September 2017

Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

29 September 2017

Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

5 September 2018

Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

5 September 2018

Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

5 September 2018

Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

5 September 2018

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

5 September 2018

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

5 September 2018

Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4832869

5 September 2018

Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/26797530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus

1 reference

https://pubmed.ncbi.nlm.nih.gov/26797530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research

1 reference

https://pubmed.ncbi.nlm.nih.gov/26797530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/26797530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26797530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus

1 reference

https://pubmed.ncbi.nlm.nih.gov/26797530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26797530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/CAS.12894

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36801223&oldid=1656673601"